Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21389646 | 0.89 | SMN1; SMN2 (0.44) | ALDH1A1SMN1; SMN2LMNATSHRHSD17B10 | |
| SCHEMBL3106023 | 0.89 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2LMNATSHRHSD17B10 | |
| SCHEMBL3104058 | 0.89 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2LMNATSHRHSD17B10 | |
| SCHEMBL11449797 | 0.88 | LMNA (0.46) | ALDH1A1SMN1; SMN2LMNATSHRHSD17B10 | |
| SCHEMBL26090526 | 0.84 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2LMNATSHRHSD17B10 | |
| SCHEMBL12204411 | 0.84 | LMNA (0.43) | ALDH1A1SMN1; SMN2LMNATSHRHSD17B10 | |
| SCHEMBL9949181 | 0.83 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2LMNATSHRHSD17B10 | |
| SCHEMBL26088665 | 0.83 | LMNA (0.41) | ALDH1A1SMN1; SMN2LMNATSHRHSD17B10 | |
| SCHEMBL27254164 | 0.83 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2LMNATSHRHSD17B10 | |
| SCHEMBL9950153 | 0.82 | SMN1; SMN2 (0.41) | ALDH1A1SMN1; SMN2LMNATSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2204394-B1 | PROCESS FOR PRODUCTION OF POLYESTER-CONTAINING FLEXIBLE POLYURETHANE FOAM, AND CATALYST COMPOSITION FOR USE IN THE PROCESS | TOSOH CORP (JP) | 2017-07-12 | — | — | EP | disclosed |
| US-8980965-B2 | Method for producing polyester type flexible polyurethane foam, and catalyst composition to be used therefor | TOSOH CORPORATION (JP) | 2015-03-17 | — | — | US | disclosed |
| CN-101835820-B | Process for production of polyester-containing flexible polyurethane foam, and catalyst composition for use in the process | TOSOH CORP | 2012-11-21 | — | — | CN | disclosed |
| US-20100256249-A1 | METHOD FOR PRODUCING POLYESTER TYPE FLEXIBLE POLYURETHANE FOAM, AND CATALYST COMPOSITION TO BE USED THEREFOR | TOSOH CORPORATION (JP) | 2010-10-07 | — | — | US | disclosed |
| CN-101835820-A | Process for production of polyester-containing flexible polyurethane foam, and catalyst composition for use in the process | TOSOH CORP | 2010-09-15 | — | — | CN | disclosed |
| EP-2204394-A1 | PROCESS FOR PRODUCTION OF POLYESTER-CONTAINING FLEXIBLE POLYURETHANE FOAM, AND CATALYST COMPOSITION FOR USE IN THE PROCESS | Tosoh Corporation (JP) | 2010-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256249-A1 | METHOD FOR PRODUCING POLYESTER TYPE FLEXIBLE POLYURETHANE FOAM, AND CATALYST COMPOSITION TO BE USED THEREFOR | OR51E2, CYP4F11, FFAR3 | ALDH1A1 2369/4885SMN1; SMN2 2713/4885LMNA 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.